Nuvalent, Inc. completed its acquisition by GlaxoSmithKline LLC on July 15, 2026, in a transaction valued at approximately $10.6 billion. Following a tender offer that expired on July 14, 2026, with 72,518,967 shares validly tendered (representing 91.3% of outstanding shares), the company merged with Harmony Row Acquisition Co. to become a wholly owned subsidiary of GlaxoSmithKline LLC. Shareholders received $124.00 per share in cash. As a result of the merger, the company's board of directors and officers resigned, and its common stock was delisted from the Nasdaq. Nuvalent, Inc. is a biotechnology company focused on developing precision medicines.

Nuvalent, Inc. entered into a merger agreement with GlaxoSmithKline LLC and its subsidiary, Harmony Row Acquisition Co., to be acquired in a cash transaction for $124.00 per share. The deal includes a tender offer for all outstanding Class A and Class B common stock, subject to a majority tender condition and antitrust clearance. Supporting stockholders, including Deerfield Management Company, L.P. and certain directors and officers, representing approximately 28% of Class A shares, have signed tender and support agreements. Nuvalent, Inc. is a biotechnology company focused on developing precision medicines for cancer.